Highlights Cytokinetics, Incorporated

Stocks

CYTK

US23282W6057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/06/2026 BST			5-day change	1st Jan Change
67.07 ^USD	-2.02%		-5.42%	+5.56%

06-09	Cytokinetics, Incorporated Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 09:18 AM
06-02	Cytokinetics Insider Sold Shares Worth $1,111,200, According to a Recent SEC Filing	MT

Highlights

06-01	Cytokinetics Launches Myqorzo in European Union with First Commercial Availability in Germany	CI
05-11	Cytokinetics Announces New Data Related to MYQORZO At ESC Heart Failure 2026	CI
05-07	Cytokinetics prices public offering of 9.8 mln shares at $71/share	RE
05-06	Cytokinetics' Rapid Growth of Myqorzo not Fully Priced in by Investors, RBC Says	MT
05-05	Cytokinetics announces proposed public offering of common stock	RE
05-05	Cytokinetics Inc - offers common stock with aggregate public offering price of $650 million - SEC filing	RE
05-05	Cytokinetics Q1 Loss Widens, Revenue Rises	MT
05-05	Earnings Flash (CYTK) Cytokinetics Posts Q1 Loss $1.67, vs. FactSet Est of $1.65 Loss	MT
05-05	Earnings Flash (CYTK) Cytokinetics, Incorporated Reports Q1 Revenue $19.4M, vs. FactSet Est of $8.5M	MT
05-05	Cytokinetics, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Cytokinetics heart disease drug improves disease symptoms in late-stage study	RE
05-05	Cytokinetics Incorporated Announces Positive Topline Results From Acacia-Hcm, The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Non-Obstructive Hypertrophic Cardiomyopathy	CI
04-20	Cytokinetics announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
02-24	Cytokinetics Q4 Loss Widens, Revenue Rises	MT
02-24	Earnings Flash (CYTK) Cytokinetics Posts Q4 Loss $-1.50, vs. FactSet Est of Loss of $-1.56	MT
02-24	Earnings Flash (CYTK) Cytokinetics, Incorporated Reports Q4 Revenue $17.8M, vs. FactSet Est of $6.9M	MT
02-24	Cytokinetics, Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-17	Cytokinetics, Incorporated Announces European Commission Approval of MYQORZO®? for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy	CI
02-17	Cytokinetics announces European Commission approval of MYQORZO	RE
02-17	Cytokinetics Reports EC Approval of Myqorzo for Obstructive Hypertrophic Cardiomyopathy	MT
01-27	Cytokinetics, Incorporated Announces MYQORZO Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms	CI
12-19	Cytokinetics Reports Myqorzo Approval for Symptomatic Obstructive Hypertrophic Cardiomyopathy	MT
12-19	Cytokinetics announces FDA approval of Myqorzo (aficamten)	RE
12-19	Cytokinetics, Incorporated Announces FDA Approval of MYQORZO for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms	CI
12-17	Cytokinetics Announces Nmpa Approval of Myqorzo®? in China for Patients with Obstructive Hypertrophic Cardiomyopathy	CI